Inhibition of transient receptor potential vanilloid-1 confers neuroprotection, reduces tumor necrosis factor-alpha, and increases IL-10 in a rat stroke model

Fundamental and Clinical Pharmacology

Volumn 31, Issue 4, 2017, Pages 420-428

  Hakimizadeh, Elham ^a   Shamsizadeh, Ali ^a   Roohbakhsh, Ali ^b   Arababadi, Mohammad Kazemi ^a   Hajizadeh, Mohammad R ^a   Shariati, Mehdi ^a   Rahmani, Mohammad R ^a   Allahtavakoli, Mohammad ^a  

^a RAFSANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

cerebral ischemia; IL 10; neuroprotection; transient receptor potential vanilloid 1; tumor necrosis factor alpha

Indexed keywords

CAPSAICIN; INTERLEUKIN 10; N (1,4 BENZODIOXAN 6 YL) 3 (4 TERT BUTYLPHENYL)ACRYLAMIDE; TUMOR NECROSIS FACTOR; 3-(4-T-BUTYLPHENYL)-N-(2,3-DIHYDROBENZO(B)(1,4)DIOXIN-6-YL)ACRYLAMIDE; ACRYLAMIDE DERIVATIVE; FUSED HETEROCYCLIC RINGS; NEUROPROTECTIVE AGENT; TRPV1 PROTEIN, RAT; VANILLOID RECEPTOR;

ADHESIVE REMOVAL TEST; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY TEMPERATURE; BRAIN EDEMA; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG EFFICACY; FORELIMB; GENE EXPRESSION; LATENT PERIOD; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CEREBROVASCULAR ACCIDENT; DISEASE MODEL; WISTAR RAT;

ACRYLAMIDES; ANIMALS; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; DISEASE MODELS, ANIMAL; INTERLEUKIN-10; MALE; NEUROPROTECTIVE AGENTS; RATS; RATS, WISTAR; STROKE; TRPV CATION CHANNELS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85017398838     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12279     Document Type: Article

References (46)

1. Loane D.J., Faden A.I. Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies. Trends Pharmacol. Sci. (2010) 31 596–604.
2. Kuroda S., Siesjo B.K. Reperfusion damage following focal ischemia: pathophysiology and therapeutic windows. Clin. Neurosci. (1997) 4 199–212.
3. Hall E.D., Detloff M.R., Johnson K., Kupina N.C. Peroxynitrite-mediated protein nitration and lipid peroxidation in a mouse model of traumatic brain injury. J. Neurotrauma (2004) 21 9–20.
4. Lapointe T.K., Altier C. The role of TRPA1 in visceral inflammation and pain. Channels (Austin) (2011) 5 525–529.
5. Xiong Y., Gu Q., Peterson P.L., Muizelaar J.P., Lee C.P. Mitochondrial dysfunction and calcium perturbation induced by traumatic brain injury. J. Neurotrauma (1997) 14 23–34.
6. Faden A.I., Demediuk P., Panter S.S., Vink R. The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science (1989) 244 798–800.
7. Morrison B. III, Eberwine J.H., Meaney D.F., McIntosh T.K. Traumatic injury induces differential expression of cell death genes in organotypic brain slice cultures determined by complementary DNA array hybridization. Neuroscience (2000) 96 131–139.
8. Leker R.R., Shohami E. Cerebral ischemia and trauma-different etiologies yet similar mechanisms: neuroprotective opportunities. Brain Res. Brain Res. Rev. (2002) 39 55–73.
9. Petrault M., Gautier S., Berezowski V. et al. Neither nefopam nor acetaminophen can be used as postoperative analgesics in a rat model of ischemic stroke. Fundam. Clin. Pharmacol. (2016) 30 12246.
10. Kadhim H.J., Duchateau J., Sebire G. Cytokines and brain injury: invited review. J. Intensive Care Med. (2008) 23 236–249.
11. Leung L., Cahill C.M. TNF-alpha and neuropathic pain – a review. J. Neuroinflammation (2010) 7 27.
12. Smith C.J., Emsley H.C., Gavin C.M. et al. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol. (2004) 4 2.
13. Allahtavakoli M., Jarrott B. Sigma-1 receptor ligand PRE-084 reduced infarct volume, neurological deficits, pro-inflammatory cytokines and enhanced anti-inflammatory cytokines after embolic stroke in rats. Brain Res. Bull. (2011) 85 219–224.
14. Ouk T., Potey C., Laprais M. et al. PPARalpha is involved in the multitargeted effects of a pretreatment with atorvastatin in experimental stroke. Fundam. Clin. Pharmacol. (2014) 28 294–302.
15. Ooboshi H., Ibayashi S., Shichita T. et al. Postischemic gene transfer of interleukin-10 protects against both focal and global brain ischemia. Circulation (2005) 111 913–919.
16. van Exel E., Gussekloo J., de Craen A.J., Bootsma-Van Der Wiel A., Frolich M., Westendorp R.G. Inflammation and stroke: the Leiden 85-Plus Study. Stroke (2002) 33 1135–1138.
17. Vriens J., Appendino G., Nilius B. Pharmacology of vanilloid transient receptor potential cation channels. Mol. Pharmacol. (2009) 75 1262–1279.
18. Mezey E., Toth Z.E., Cortright D.N. et al. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc. Natl Acad. Sci. USA (2000) 97 3655–3660.
19. Zielinska M., Jarmuz A., Wasilewski A., Salaga M., Fichna J. Role of transient receptor potential channels in intestinal inflammation and visceral pain: novel targets in inflammatory bowel diseases. Inflamm. Bowel Dis. (2015) 21 419–427.
20. Keeble J., Russell F., Curtis B., Starr A., Pinter E., Brain S.D. Involvement of transient receptor potential vanilloid 1 in the vascular and hyperalgesic components of joint inflammation. Arthritis Rheum. (2005) 52 3248–3256.
21. Miyanohara J., Shirakawa H., Sanpei K., Nakagawa T., Kaneko S. A pathophysiological role of TRPV1 in ischemic injury after transient focal cerebral ischemia in mice. Biochem. Biophys. Res. Commun. (2015) 467 478–483.
22. Institute of Laboratory Animal Resources. Guide for the care and use of laboratory animals, 7th edn. Academy Press, Washington, DC, 1996.
23. Khatibi N.H., Jadhav V., Charles S. et al. Capsaicin pre-treatment provides neurovascular protection against neonatal hypoxic-ischemic brain injury in rats. Acta Neurochir. Suppl. (2011) 111 225–230.
24. Fu J., Bottegoni G., Sasso O. et al. A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nat. Neurosci. (2012) 15 64–69.
25. Tamura A., Graham D.I., McCulloch J., Teasdale G.M. Focal cerebral ischaemia in the rat: 1. Description of technique and early neuropathological consequences following middle cerebral artery occlusion. J. Cereb. Blood Flow Metab. (1981) 1 53–60.
26. Xing B., Chen H., Zhang M. et al. Ischemic postconditioning inhibits apoptosis after focal cerebral ischemia/reperfusion injury in the rat. Stroke (2008) 39 2362–2369.
27. Allahtavakoli M., Shabanzadeh A., Roohbakhsh A., Pourshanazari A. Combination therapy of rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, and NMDA receptor antagonist (MK-801) on experimental embolic stroke in rats. Basic Clin. Pharmacol. Toxicol. (2007) 101 309–314.
28. Zheng Z., Yenari M.A. Post-ischemic inflammation: molecular mechanisms and therapeutic implications. Neurol. Res. (2004) 26 884–892.
29. Hattori K., Lee H., Hurn P.D., Crain B.J., Traystman R.J., DeVries A.C. Cognitive deficits after focal cerebral ischemia in mice. Stroke (2000) 31 1939–1944.
30. Liu N., Chen R., Du H., Wang J., Zhang Y., Wen J. Expression of IL-10 and TNF-α in rats with cerebral infarction after transplantation with mesenchymal stem cells. Cell. Mol. Immunol. (2009) 6 207.
31. Tarkowski E., Rosengren L., Blomstrand C. et al. Intrathecal release of pro-and anti-inflammatory cytokines during stroke. Clin. Exp. Immunol. (1997) 110 492–499.
32. John T., Muller R.D., Oberholzer A. et al. Interleukin-10 modulates pro-apoptotic effects of TNF-alpha in human articular chondrocytes in vitro. Cytokine (2007) 40 226–234.
33. Borghi S.M., Carvalho T.T., Staurengo-Ferrari L. et al. Vitexin inhibits inflammatory pain in mice by targeting TRPV1, oxidative stress, and cytokines. J. Nat. Prod. (2013) 76 1141–1149.
34. Rennick D., Davidson N., Berg D. Interleukin-10 gene knock-out mice: a model of chronic inflammation. Clin. Immunol. Immunopathol. (1995) 76 S174–S178.
35. Moore K.W., O'Garra A., de Waal Malefyt R., Vieira P., Mosmann T.R. Interleukin-10. Annu. Rev. Immunol. (1993) 11 165–190.
36. Pinto A., Tuttolomondo A., Di Raimondo D. et al. Cardiovascular risk profile and morbidity in subjects affected by type 2 diabetes mellitus with and without diabetic foot. Metabolism (2008) 57 676–682.
37. Tuttolomondo A., Pecoraro R., Pinto A. Studies of selective TNF inhibitors in the treatment of brain injury from stroke and trauma: a review of the evidence to date. Drug Des. Devel. Ther. (2014) 8 2221–2238.
38. Hernandez-Guillamon M., Mawhirt S., Blais S. et al. Sequential amyloid-β degradation by the matrix metalloproteases MMP-2 and MMP-9. J. Biol. Chem. (2015) 290 15078–15091.
39. Planells-Cases R., Valente P., Ferrer-Montiel A., Qin F., Szallasi A. Complex regulation of TRPV1 and related thermo-TRPs: implications for therapeutic intervention. Adv. Exp. Med. Biol. (2011) 704 491–515.
40. Lai T.W., Zhang S., Wang Y.T. Excitotoxicity and stroke: identifying novel targets for neuroprotection. Prog. Neurobiol. (2014) 115 157–188.
41. Pegorini S., Braida D., Verzoni C. et al. Capsaicin exhibits neuroprotective effects in a model of transient global cerebral ischemia in Mongolian gerbils. Br. J. Pharmacol. (2005) 144 727–735.
42. Cao Z., Balasubramanian A., Marrelli S.P. Pharmacologically induced hypothermia via TRPV1 channel agonism provides neuroprotection following ischemic stroke when initiated 90 min after reperfusion. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2014) 306 R149–R156.
43. Muzzi M., Felici R., Cavone L. et al. Ischemic neuroprotection by TRPV1 receptor-induced hypothermia. J. Cereb. Blood Flow Metab. (2012) 32 978–982.
44. Lehto S.G., Tamir R., Deng H. et al. Antihyperalgesic effects of (R, E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluorom ethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats. J. Pharmacol. Exp. Ther. (2008) 326 218–229.
45. Chen L., Marko L., Kassmann M., Zhu Y., Wu K., Gollasch M. Role of TRPV1 channels in ischemia/reperfusion-induced acute kidney injury. PLoS One (2014) 9 e109842.
46. Schomacher M., Muller H.D., Sommer C., Schwab S., Schabitz W.R. Endocannabinoids mediate neuroprotection after transient focal cerebral ischemia. Brain Res. (2008) 1240 213–220.